Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes

• Published in: Journal of diabetes science and technology Vol. 13; no. 2; pp. 254 - 258
• Main Authors: Welsh, John B., Zhang, Xiaohe, Puhr, Sarah A., Johnson, Terri Kang, Walker, Tomas C., Balo, Andrew K., Price, David
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2019
• Subjects: Technology Reports; factory-calibrated; advanced algorithm; continuous glucose monitoring; MARD; clinical accuracy; glucose sensor performance
• ISSN: 1932-2968; 1932-2968; 1932-3107
• DOI: 10.1177/1932296818798816

Background: The perceived value and consistent use of continuous glucose monitoring (CGM) systems depends in part on their accuracy. We assessed the performance of a sixth-generation CGM system (Dexcom G6) in children and adolescents. Methods: Forty-nine participants (6-17 years of age, mean ± SD of 13.5 ± 3.3 years), all with type 1 diabetes, enrolled and data were available from 37. Each participant wore 1 sensor for up to 10 days and was asked to undergo an in-clinic visit lasting 6-12 hours for frequent blood glucose (BG) sample testing on one of the sensor wear days. Estimated glucose values (EGVs) from the G6 system were compared with venous BG values measured with a laboratory reference instrument (YSI). Results: The overall mean absolute relative difference (MARD) for 1387 EGV-YSI pairs was 7.7%, and the overall percentage of EGVs within 20% or 20 mg/dL of the YSI reference value (for YSI > or ⩽100 mg/dL, respectively, the “%20/20”) was 96.2%. The %20/20 was 92.1% on Day 1 and 91.0% on Day 10 of sensor wear. For EGVs <70 mg/dL, 92.6% of the YSI values were within 20 mg/dL and for EGVs >250 mg/dL, 100% of the YSI values were within 20%. Differences between EGVs and YSI values in over 99.9% of the pairs posed no or only slight clinical risk as evaluated by surveillance error grid analysis. Conclusions: The accuracy of the G6 CGM system in pediatrics may encourage consistent use of the system and contribute to improved glycemic outcomes in this population.